Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19

To explore the efficacy and safety of Umbilical cord mesenchymal stem cells in the treatment of long COVID-19

Inclusion Criteria:The age ranges from 18 to 85 (inclusive), regardless of gender.Patients with Confirmed SARS-CoV-2 infection, according to the consensus of the Chinese diagnostic criteria for COVID-19 (Tentative tenth Edition).Patients with symptoms of long COVID-19 3 months from the onset of COVID-19, lasting for at least 2 months, and the symptoms cannot be explained by other diseases.Be expected to live longer than 1 year.Volunteer to participate in this clinical study and sign the written informed consent.Exclusion Criteria:Those who are using immunosuppressive drugs or long-term immunosuppressive drugs after organ transplantation.T lymphocyte abnormality, HIV positive.Highly allergic or have a history of severe allergy.Pregnant and lactating women.Patients with severe autoimmune disease history;Patients with uncontrolled chronic diseases or serious complications;Patients with malignant tumors;Patients with pulmonary embolism, acute coronary syndrome, cerebral embolism or at high risk of thromboembolism;Patients with severe organ dysfunctionOther situations that the researchers think are not suitable for participating in this study